Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.
Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
In connection with Curasight's Q2 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.
Vi havde i dag fornøjelsen af Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær, som præsenterede resultaterne for første halvår af 2026 samt svarede på spørgsmål
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Curasight ventes at offentliggøre sin delårsrapport for første halvår 2026 den 27. august 2026. Den 31. august kl. 12.00 vil CEO Ulrich Krasilnikoff og CSO professor Andreas Kjær præsentere periodens resultater og status på selskabets kliniske pipeline, efterfulgt af en Q&A-session.
Udsigt til en marginal negativ åbning i Europa. Warsh tale samt fornyet uro i Mellemøsten presser. Herhjemme fokus på analytikerændringer. Gæst i studiet her til morgen er Adam Lange fra Gubra, hvor vi ser ind de mange nyheder fra fedmepipelinen det sidste halve år.
I dag afholder vi to online investorevents. Kl. 12:00 præsenterer Curasight CEO Ulrich Krasilnikoff og CSO professor Andreas Kjær delårsrapporten for første halvår 2026. Kl. 13:30 præsenterer Impero CEO Rikke Stampe Skov og CFO Kasper Lihn resultaterne for H1 2026. Tilmeld dig og stil dine spørgsmål allerede nu.
Curasight reported Q2 2026 this morning and, alongside the figures, moved the timing of its three remaining clinical read-outs into 2027, thereby removing some near-term catalysts, but also announced expansions to the Phase I/IIa basket trial.
Udsigt til positiv åbning i Europa her til morgen efter Nvidia leverede. Vi ser ind på reaktioner ovenpå gårsdagens danske regnskabsbyge. Gæst i studiet her til morgen er Søren Truelsen, Nordic Bloom for at se ind i den kommende US IPO bølge.
Udsigt til en negativ åbning fra morgenstunden efter kraftige fald i asien samt i USA handlen i går i teknologisektoren: Micron og udsalg blandt hyperscalers spøger. Herhjemme fokus på blandt andet Demant, Coloplast og Torm
Curasight announced this morning that it has completed a directed issue of approximately DKK 20m before transaction costs. The issue extends the company's financing horizon. Management now assesses that the net proceeds are sufficient to fund operations through the end of H1 2027.
